Amgen Optimistic Over Inflammation Biosimilars Ahead Of Ustekinumab
Patient Enrollment Complete For Phase III Stelara Biosimilar Study
Amgen has once again touched on its impending expansion into US inflammation/immunology biosimilars, with launches for adalimumab and ustekinumab scheduled for the coming years.
